Top-Rated StocksTop-RatedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $128.92 -4.85 (-3.63%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$126.82▼$134.5550-Day Range$125.34▼$156.7552-Week Range$55.25▼$173.25Volume1.16 million shsAverage Volume1.33 million shsMarket Capitalization$12.19 billionP/E Ratio1,172.00Dividend YieldN/APrice Target$186.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.95 Rating ScoreUpside/Downside44.4% Upside$186.22 Price TargetShort InterestBearish7.12% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.36Based on 17 Articles This WeekInsider TradingSelling Shares$8.40 M Sold Last QuarterProj. Earnings Growth603.40%From $1.47 to $10.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.84 out of 5 starsMedical Sector26th out of 910 stocksPharmaceutical Preparations Industry9th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 16 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.12% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 0.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 2.4 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.Search Interest19 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold 69.49% more of their company's stock than they have bought. Specifically, they have bought $4,955,684.00 in company stock and sold $8,399,586.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 603.40% in the coming year, from $1.47 to $10.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,172.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,172.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 11.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesSeptember 4 at 4:20 AM | insidertrades.comInsider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sells 5,985 Shares of StockAugust 21, 2024 | insidertrades.comInsider Buying: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Acquires 37,038 Shares of StockSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 19, 2024 | marketbeat.comThis Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.September 7 at 8:06 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Danaher (DHR)September 7 at 8:06 AM | benzinga.comUnveiling 26 Analyst Insights On Sarepta TherapeuticsSeptember 5 at 1:19 PM | finance.yahoo.comSarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic YearSeptember 5 at 8:17 AM | insidermonkey.com12 Best Biotech Stocks To Invest In According To Hedge FundsSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…September 4 at 9:43 PM | ca.finance.yahoo.comSRPT Aug 2025 150.000 callSeptember 4 at 9:43 PM | ca.finance.yahoo.comSRPT Jan 2025 160.000 callSeptember 4 at 4:25 AM | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Ian Michael Estepan Sells 5,985 SharesAugust 31, 2024 | ca.finance.yahoo.comSRPT Aug 2024 180.000 callAugust 31, 2024 | ca.finance.yahoo.comSRPT Dec 2024 110.000 callAugust 31, 2024 | americanbankingnews.comSarepta Therapeutics, Inc. to Post Q4 2024 Earnings of $0.90 Per Share, Zacks Research Forecasts (NASDAQ:SRPT)August 30, 2024 | ca.finance.yahoo.comSRPT Sep 2024 95.000 callAugust 30, 2024 | ca.finance.yahoo.comSRPT Feb 2025 230.000 callAugust 30, 2024 | finance.yahoo.comSarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$186.22 High Stock Price Target$235.00 Low Stock Price Target$109.00 Potential Upside/Downside+44.4%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio1,172.00 Forward P/E Ratio87.70 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins3.14% Pretax Margin4.13% Return on Equity5.32% Return on Assets1.50% Debt Debt-to-Equity Ratio1.05 Current Ratio3.90 Quick Ratio3.19 Sales & Book Value Annual Sales$1.50 billion Price / Sales8.10 Cash FlowN/A Price / Cash FlowN/A Book Value$11.29 per share Price / Book11.42Miscellaneous Outstanding Shares94,524,000Free Float87,246,000Market Cap$12.19 billion OptionableOptionable Beta0.81 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSJazz PharmaceuticalsNASDAQ:JAZZMirati TherapeuticsNASDAQ:MRTXACADIA PharmaceuticalsNASDAQ:ACADPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInsiders & InstitutionsIan Michael EstepanSold 5,985 sharesTotal: $822,099.60 ($137.36/share)Clearbridge Investments LLCBought 86,138 shares on 8/27/2024Ownership: 0.251%Teachers Retirement System of The State of KentuckyBought 30,200 shares on 8/26/2024Ownership: 0.032%Cetera Investment AdvisersBought 1,022 shares on 8/22/2024Ownership: 0.014%Truist Financial CorpBought 1,857 shares on 8/21/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $96.43 at the beginning of the year. Since then, SRPT stock has increased by 33.7% and is now trading at $128.92. View the best growth stocks for 2024 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its earnings results on Wednesday, August, 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. The business's revenue was up 38.9% on a year-over-year basis. What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional shareholders include Avoro Capital Advisors LLC (3.17%), Susquehanna International Group LLP, Thrivent Financial for Lutherans (0.68%) and Federated Hermes Inc. (0.54%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor, Stephen Mayo and Louise Rodino-Klapac. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA) and Netflix (NFLX). This page (NASDAQ:SRPT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
